Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
Cancer Treatment Reports
|
November 1, 1986
Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas
V A Levin, S Phuphanich, H C Liu, et al.
Neuro-Oncology
|
September 29, 2011
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma
L B Nabors, J G Supko, M Rosenfeld, et al.
Magnetic Resonance Imaging
|
January 1, 1995
Comparison of supervised MRI segmentation methods for tumor volume determination during therapy
M Vaidyanathan, L P Clarke, R P Velthuizen, et al.
The Journal of Pediatric Endocrinology
|
April 1, 1993
Neurotransmitter control of growth hormone secretion in children after cranial radiation therapy
E V Jorgensen, I D Schwartz, E Hvizdala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 1999
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors
M J Glantz, K A Jaeckle, M C Chamberlain, et al.
Journal of Neuro-Oncology
|
October 19, 2015
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients
J J Raizer, P Giglio, J Hu, et al.
British Journal of Cancer
|
February 13, 2001
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine
K A Jaeckle, S Phuphanich, M J Bent, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
Cancer Treatment Reports
|
November 1, 1986
Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas
V A Levin, S Phuphanich, H C Liu, et al.
Neuro-Oncology
|
September 29, 2011
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma
L B Nabors, J G Supko, M Rosenfeld, et al.
Magnetic Resonance Imaging
|
January 1, 1995
Comparison of supervised MRI segmentation methods for tumor volume determination during therapy
M Vaidyanathan, L P Clarke, R P Velthuizen, et al.
The Journal of Pediatric Endocrinology
|
April 1, 1993
Neurotransmitter control of growth hormone secretion in children after cranial radiation therapy
E V Jorgensen, I D Schwartz, E Hvizdala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 1999
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors
M J Glantz, K A Jaeckle, M C Chamberlain, et al.
Journal of Neuro-Oncology
|
October 19, 2015
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients
J J Raizer, P Giglio, J Hu, et al.
British Journal of Cancer
|
February 13, 2001
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine
K A Jaeckle, S Phuphanich, M J Bent, et al.
Page
of 3